Omalizumab for treatment of refractory severe atopic dermatitis. A pediatric perspective.
atopic dermatitis
eczema
pruritus
therapy-systemic
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
12
03
2020
revised:
20
04
2020
accepted:
02
05
2020
pubmed:
8
5
2020
medline:
15
5
2021
entrez:
8
5
2020
Statut:
ppublish
Résumé
Omalizumab is a monoclonal antibody, targeting Fc receptor of IgE, approved for the treatment of allergic asthma and chronic spontaneous urticaria. Its utility in atopic dermatitis appears controversial from data in literature since the molecule is well tolerated but it seems less effective than other medications used in adult patients (eg, Dupilumab). At present, the use of Dupilumab is not approved in pediatric patients therefore there are no second level treatments available in this age group. Here we report two clinical cases of patients (15 and 16 years old) suffering from both atopic dermatitis and asthma, treated with Omalizumab. Our experience suggests that atopic eczema of young patients with allergic comorbidities can benefit from asthma treatment with Omalizumab observing improvement on both conditions.
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Omalizumab
2P471X1Z11
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13519Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Al-Shobaili HA, Ahmed AA, Alnomair N, Alobead ZA, Rasheed Z. Molecular genetic of atopic dermatitis: an update. Int J Health Sci (Qassim). 2016;10:96-120.
Deckers IA, McLean S, Linssen S, Mommers M, van Schayck CP, Sheikh A. Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies. PloS One. 2012;7:e39803.
Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006;60:984-992.
Broeders JA, Ahmed Ali U, Fischer G. Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: a 15-year experience. J Am Acad Dermatol. 2016;75:410-419.
Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71:327-349.
Vaccaro M, Cannavò SP, Imbesi S, et al. Increased serum levels of interleukin-23 circulating in patients with non-segmental generalized vitiligo. Int J Dermatol. 2015;54:672-674.
Deleanu D, Nedelea I. Biological therapies for atopic dermatitis: an update. Exp Ther Med. 2019;17:1061-1067.
Papaianni V, Guarneri F, Vaccaro M, Borgia F, Guarneri C, Cannavò SP. From regulatory limitations to new opportunities: real-life experience on the effectiveness of short courses of omalizumab in the treatment of chronic idiopatic urticarial. Dermatol Ther. 2020;33:e13188.
Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011;139:28-35.
Lacombe-Barrios J, Bégin P, Paradis L, Hatami A, Paradis J, Des RA. Anti-IgE therapy and severe atopic dermatitis: a pediatric perspective. J Am Acad Dermatol. 2013;69:832-834.
García M, Durán-Crane A, Chapman E, García E. Omalizumab as an adjuvant therapy for treating severe atopic dermatitis in children. A serie of cases. Rev Alerg Mex. 2019;66:282-291.
Holm J, Agner T, Sand C, Thomsen SF. Omalizumab for atopic dermatitis: case series and a systematic review of the literature. Int J Dermatol. 2017;56:18-26.
Snast I, Reiter O, Hodak E, Friedland R, Mimouni D, Leshem YA. Are biologics efficacious in atopic dermatitis? A systematic review and meta-analysis. Am J Clin Dermatol. 2018;19:145-165.
Nguyen HL, Anderson KR, Tollefson MM. New and emerging therapies for pediatric atopic dermatitis. Paediatr Drugs. 2019;21:239-260.
Siegfried EC, Igelman S, Jaworsk JC, et al. Use of Dupilumab in pediatric atopic dermatitis: access, dosing and implications for managing severe atopic dermatitis. Pediatr Dermatol. 2019;36:172-176.
Chan S, Cornelius V, Cro S, Harper JI, Lack G. Treatment effect of Omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial. JAMA Pediatr. 2019;174:29. https://doi.org/10.1001/jamapediatrics.2019.4476.